Yumab
Private Company
Funding information not available
Overview
YUMAB is a specialized German contract research organization (CRO) and technology provider focused exclusively on therapeutic antibody discovery and development. Leveraging nearly 30 years of collective expertise and a proprietary, human-derived antibody library platform, the company offers end-to-end services from target identification to lead optimization, including antibody engineering and humanization. As a private, revenue-generating entity, YUMAB serves as a strategic partner for pharma and biotech companies, accelerating and de-risking their antibody drug development programs through flexible contract research agreements.
Technology Platform
Proprietary in-vitro antibody discovery platform featuring a human-derived universal library (>10^11 clones), cell-compatible selection and screening technologies, and capabilities for antibody engineering, humanization, and format development (e.g., bispecifics). Includes innovative Mammalian Display technology.
Opportunities
Risk Factors
Competitive Landscape
YUMAB competes in the crowded antibody discovery services market against large CROs (e.g., Lonza, Charles River), specialized platform companies (e.g., AbCellera, Distributed Bio), and technology providers (e.g., Twist Bioscience, Ligand's OmniAb). Its differentiation lies in its deep academic heritage, focus on challenging targets using cell-based screening, and integrated service offering from library to engineered lead.